-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The RATIONALE 304 study is a trial of tislelizumab (an anti-PD-1 antibody) in combination with platinum and pemetrexed versus chemotherapy alone in first-line treatment of patients with stage IIIB or IV non-squamous non-small cell lung cancer (nsq- NSCLC ).
Lung cancerNSCLC
A total of 334 nsq-NSCLC patients were enrolled in the study and randomly assigned in a 2:1 ratio to tislelizumab combined with chemotherapy (group A, n=223) and chemotherapy alone (group B, n=111).
Research design
Figure 1 RATIONALE 304 study design
The interim analysis showed that in patients with advanced non-squamous NSCLC, the combination of tislelizumab significantly improved PFS compared with chemotherapy alone (IRC assessment: P=0.
In a preliminary analysis of RATIONALE-304 (NCT03663205), tislelizumab (TIS) plus platinum-based chemotherapy significantly improved clinical outcomes in untreated advanced nsq-NSCLC compared with chemotherapy alone (by independent review committee [ The median progression-free survival [PFS] assessed by IRC] was 9.
The nsq-NSCLC patients were randomly divided into TIS+platinum+pemetrexed group and platinum+pemetrexed group according to the ratio of 2:1
statistics
Of the 325 treated patients without EGFR-sensitizing mutations in the RATIONALE-304 study, 177 (54.
In this retrospective analysis, neither tTMB nor bTMB was significantly associated with PFS benefit, suggesting that tTMB and bTMB have limited clinical utility in TIS+chemotherapy as first-line treatment for advanced nsq-NSCLC
leave a message here